AREDS2 multivitamin (full formulation)
Multi-nutrient formula tested in the NEJM-tier AREDS2 RCT, the evidence-based supplement for slowing AMD progression.
Why
The AREDS2 formula is the specific multi-nutrient combination tested in the Age-Related Eye Disease Study 2 (Chew JAMA 2013): vitamin C 500 mg, vitamin E 400 IU, zinc oxide 80 mg (later reduced to 25 mg without efficacy loss), cupric oxide 2 mg, lutein 10 mg, zeaxanthin 2 mg. Designed for adults with intermediate or advanced AMD in at least one eye. Beta-carotene from the original AREDS formula was removed because of lung-cancer risk in smokers.
How it works
Combined antioxidant (vit C, E) and trace-mineral (zinc, copper) effects on macular oxidative stress and inflammation; lutein/zeaxanthin specifically concentrate in macular pigment. Synergistic effects greater than individual components in the original AREDS trial.
Expected onset · AMD progression endpoints assessed over 3–5 years
How to take
Dosage
AREDS2 daily formula: vit C 500 mg, vit E 400 IU, zinc oxide 25–80 mg, cupric oxide 2 mg, lutein 10 mg, zeaxanthin 2 mg. Once or split twice daily with food.
Timing
With meals; split twice daily for better tolerability
On the label
Look for 'AREDS2 formula' explicitly, the specific dosing matters and varies between OTC products. PreserVision AREDS2 is the brand most-aligned with the trial formula.
Ideal for
Adults with intermediate (large drusen) or advanced AMD in one eye; under ophthalmology guidance to confirm the staging and the appropriateness of supplementation.
Safety
Evidence
AREDS (2001 Arch Ophthalmol) original formula reduced 5-year risk of advanced AMD by ~25% in intermediate AMD. AREDS2 (2013 JAMA) replaced beta-carotene with lutein/zeaxanthin without efficacy loss and with improved smoker safety. Chew 2022 JAMA Ophthalmol 10-year follow-up confirmed sustained benefit and the safety of zinc 25 mg (vs original 80 mg).
- AREDS2 Research Group, JAMA 2013, lutein + zeaxanthin and omega-3 fatty acids for AMD: AREDS2 RCT (n=4,203)
- AREDS Research Group, Arch Ophthalmol 2001, a randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for AMD and vision loss: AREDS report no. 8
- Chew et al., JAMA Ophthalmol 2022, long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids: AREDS2 10-year follow-up
Where to get it
Shop AREDS2 multivitamin (full formulation) on AmazonSponsored · As an Amazon Associate, Healicus earns from qualifying purchases.